Literature DB >> 11955717

Up-regulation of the G(q/11alpha) protein and protein kinase C during the development of sensitization to morphine-induced hyperlocomotion.

M Narita1, K Mizuo, M Shibasaki, M Narita1, T Suzuki.   

Abstract

It has been recognized that protein kinase C (PKC) pathway is involved in the synaptic plasticity. The present study was then designed to examine the changes in G(q/11alpha) and G(betagamma) subunits and PKC activity on sensitization to the morphine-induced hyperlocomotion. Repeated subcutaneous administration of morphine every 72 h produced sensitization to the morphine-induced hyperlocomotion. In morphine-sensitized mice, the protein level of G(q/11alpha) subunit in the limbic forebrain including the nucleus accumbens, but not in the lower midbrain containing the ventral tegmental area, was markedly increased, whereas the levels of G(betagamma) subunit were not altered in either areas. Under these conditions, the levels of membrane-bound phosphorylated-PKC in the limbic forebrain was clearly up-regulated by intermittent morphine treatment. We also found the lack of changes in the level of the regulator of G protein signaling 4, which is a specific G(q/11alpha)-dependent GTPase activating protein, in the limbic forebrain obtained from morphine-sensitized mice. These results indicate that the up-regulation of membrane-bound PKC following intermittent morphine treatment results from the increase in levels of G(q/11alpha) protein. In order to investigate the direct involvement of PKC in the morphine-induced hyperlocomotion, the locomotion induced by acute morphine treatment in the presence or absence of a PKC inhibitor was measured. A specific PKC inhibitor Ro-32-0432 given intracerebroventricularly caused a dose-dependent inhibition of morphine-induced hyperlocomotion. These findings suggest that the up-regulation of G(q/11alpha)-dependent PKC activity in membranes of the limbic forebrain is implicated in the development of sensitization to morphine-induced hyperlocomotion in mice.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11955717     DOI: 10.1016/s0306-4522(01)00515-2

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  5 in total

1.  Changes in accumbal and pallidal pCREB and deltaFosB in morphine-sensitized rats: correlations with receptor-evoked electrophysiological measures in the ventral pallidum.

Authors:  John McDaid; Jeanine E Dallimore; Alexander R Mackie; T Celeste Napier
Journal:  Neuropsychopharmacology       Date:  2006-06       Impact factor: 7.853

2.  Pre-treatment with a PKC or PKA inhibitor prevents the development of morphine tolerance but not physical dependence in mice.

Authors:  Bichoy H Gabra; Chris P Bailey; Eamonn Kelly; Forrest L Smith; Graeme Henderson; William L Dewey
Journal:  Brain Res       Date:  2008-04-24       Impact factor: 3.252

3.  Increased response to morphine in mice lacking protein kinase C epsilon.

Authors:  P M Newton; J A Kim; A J McGeehan; J P Paredes; K Chu; M J Wallace; A J Roberts; C W Hodge; R O Messing
Journal:  Genes Brain Behav       Date:  2006-08-07       Impact factor: 3.449

4.  Molecular evidence for the functional role of dopamine D3 receptor in the morphine-induced rewarding effect and hyperlocomotion.

Authors:  Minoru Narita; Keisuke Mizuo; Hirokazu Mizoguchi; Mamoru Sakata; Michiko Narita; Leon F Tseng; Tsutomu Suzuki
Journal:  J Neurosci       Date:  2003-02-01       Impact factor: 6.167

5.  Blockade of MCH1 receptor signalling ameliorates obesity and related hepatic steatosis in ovariectomized mice.

Authors:  A Gomori; A Ishihara; M Ito; H Matsushita; M Ito; S Mashiko; H Iwaasa; M Matsuda; M A Bednarek; S Qian; D J Macneil; A Kanatani
Journal:  Br J Pharmacol       Date:  2007-05-21       Impact factor: 8.739

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.